Nizatidine

Nizatidine is an H2‑receptor antagonist that reduces gastric acid secretion, making it useful in several acid‑related gastrointestinal conditions.

• Peptic ulcer disease: promotes ulcer healing by lowering gastric acidity and reducing ulcer‑related pain.
• Gastro‑oesophageal reflux disease (GERD): decreases reflux symptoms and esophageal irritation through acid suppression.
• Erosive esophagitis: facilitates mucosal recovery by limiting acid‑induced damage to the esophageal lining.
• Ulcer recurrence prevention: maintains low gastric acid levels to help prevent the return of previously healed ulcers.

• Nizatidine acts as a competitive antagonist at histamine H2 receptors located on the basolateral membrane of gastric parietal cells. By blocking histamine binding, it inhibits the cAMP‑mediated activation of the H⁺/K⁺‑ATPase pump, leading to a reduction in basal and stimulated gastric acid secretion. This effect lowers gastric acidity and promotes healing of acid‑related lesions. The inhibition is dose‑dependent and persists for several hours after dosing.

Nizatidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Dizziness or vertigo: may occur shortly after dosing.
• Gastrointestinal disturbances: nausea, diarrhea or constipation.
• Skin reactions: mild rash or pruritus.
• Fatigue: feeling of tiredness or reduced energy.
• Taste alteration: metallic or altered taste perception.
• Dry mouth: reduced salivation.
• Insomnia: difficulty falling asleep.

Serious or Rare Side Effects

• Hematologic abnormalities: neutropenia, thrombocytopenia or agranulocytosis.
• Hepatic dysfunction: elevated transaminases or hepatitis.
• Severe hypersensitivity: anaphylaxis, angioedema or Stevens‑Johnson syndrome.
• Acute interstitial nephritis: renal function decline with eosinophilia.
• Pancreatitis: abdominal pain with elevated enzymes.
• Cardiac arrhythmia: rare QT prolongation.

When prescribing Nizatidine, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal function: dose adjustment may be needed in patients with impaired clearance.
• Monitor liver enzymes: hepatic impairment can increase systemic exposure.
• Avoid in known hypersensitivity: discontinue if rash, angioedema or anaphylaxis occurs.
• Use cautiously in the elderly: increased risk of confusion and dizziness.
• Review concomitant medications: potential interactions may require dose modifications.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Nizatidine can affect the absorption or metabolism of several other medicines.

Major Interactions (Avoid)

• Ketoconazole, itraconazole, or other azole antifungals: reduced absorption due to increased gastric pH.
• Atazanavir or other protease inhibitors: decreased plasma concentrations compromising antiviral efficacy.
• Warfarin: enhanced anticoagulant effect may increase bleeding risk.

Moderate Interactions (Monitor Closely)

• Digoxin: higher serum levels may occur; monitor therapeutic range.
• Theophylline: possible increase in plasma concentration; observe for toxicity.
• Antidepressants (e.g., citalopram): may require dose adjustment due to altered metabolism.